Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion
Authors:
- Sophia Y. ChenSCSophia Y. Chen
- Heng-Chung KungHKHeng-Chung Kung
- Birginia EspinozaBEBirginia Espinoza
- India WashingtonIWIndia Washington
- Kai ChenKCKai Chen
- Jianxin WangJWJianxin Wang
- Haley ZlomkeHZHaley Zlomke
- Rulin WangRWRulin Wang
- Michael PickupMPMichael Pickup
- William R. BurnsWBWilliam R. Burns
- Juan FuJFJuan Fu
Open Access
- 8 November 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (21)
Abstract
The dual tumor-suppressive and -promoting functions of TGF-β signaling has made its targeting challenging. We examined the effects of TGF-β depletion by AVID200/BMS-986416 (TGF-β-TRAP), a TGF-β ligand trap, on the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) murine models with different organ-specific metastasis. Our study demonstrated that TGF-β-TRAP potentiates the efficacy of anti–programmed cell death 1 (anti–PD-1) in a PDAC orthotopic murine model with liver metastasis tropism, significantly reducing liver metastases. We further demonstrated the heterogeneous response of cytotoxic effector T cells to combination TGF-β-TRAP and anti–PD-1 treatment across several tumor models. Single-nuclear RNA sequencing suggested that TGF-β-TRAP modulates cancer-associated fibroblast (CAF) heterogeneity and suppresses neutrophil degranulation and CD4 + T cell response to neutrophil degranulation. Ligand-receptor analysis indicated that TGF-β-TRAP may modulate the CCL5/CCR5 axis as well as costimulatory and checkpoint signaling from CAFs and myeloid cells. Notably, the most highly expressed ligands of CCR5 shifted from the immunosuppressive CCL5 to CCL7 and CCL8, which may mediate the immune agonist activity of CCR5 following TGF-β-TRAP and anti–PD-1 combination treatment. This study suggested that TGF-β depletion modulates CAF heterogeneity and potentially reprograms CAFs and myeloid cells into antitumor immune agonists in PDAC, supporting the validation of such effects in human specimens.Keywords
This publication has 62 references indexed in Scilit:
- Integrated analysis of multimodal single-cell dataCell, 2021
- Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemiaExperimental Hematology, 2020
- Clinical development of therapies targeting TGFβ: current knowledge and future perspectivesAnnals of Oncology, 2020
- Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic CancerCell, 2019
- Transforming Growth Factor-β Signaling in Immunity and CancerImmunity, 2019
- Targeting TGF-β Signaling in CancerTrends in Cancer, 2017
- Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitmentCancer Immunology, Immunotherapy, 2012
- Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 inductionCancer Letters, 2011
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillanceCancer Cell, 2005